A potential role for caveolin-1 in VEGF-induced fibronectin upregulation in mesangial cells: Involvement of VEGFR2 and Src

American Journal of Physiology - Renal Physiology

Volumn 304, Issue 6, 2013, Pages

  Wu, Tingting ^a   Zhang, Baifang ^a   Ye, Feng ^a   Xiao, Zeling ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Caveolin 1; Extracellular matrix; Glomerular sclerosis

Indexed keywords

2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; CAVEOLIN 1; COLLAGEN TYPE 4; CYCLODEXTRIN; FASUDIL; FIBRONECTIN; PROTEIN KINASE P60; RHO KINASE; SEMAXANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; PROTEIN TYROSINE KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAVEOLA; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; EXTRACELLULAR MATRIX; FLUORESCENCE MICROSCOPY; GENE OVEREXPRESSION; GLOMERULOSCLEROSIS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MESANGIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SURVIVAL; TRANSCRIPTION INITIATION; UPREGULATION; WESTERN BLOTTING; ANIMAL; CELL CULTURE; MALE; METABOLISM; PHOSPHORYLATION; SPRAGUE DAWLEY RAT;

ANIMALS; CAVEOLAE; CAVEOLIN 1; CELLS, CULTURED; FIBRONECTINS; MALE; MESANGIAL CELLS; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RHOA GTP-BINDING PROTEIN; SRC-FAMILY KINASES; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

MLCS; MLOWN;

EID: 84877929962     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00294.2012     Document Type: Article

References (69)

1. Amemiya T, Sasamura H, Mifune M, Kitamura Y, Hirahashi J, Hayashi M, Saruta T. Vascular endothelial growth factor activates MAP kinase and enhances collagen synthesis in human mesangial cells. Kidney Int 56: 2055-2063, 1999.
2. Anderson RG. The caveolae membrane system. Annu Rev Biochem 67: 199-225, 1998.
3. Bortoloso E, Del Prete D, Dalla Vestra M, Gambaro G, Saller A, Antonucci F, Baggio B, Anglani F, Fioretto P. Quantitave and qualitative changes in vascular endothelial growth factor gene expression in glomeruli of patients with type 2 diabetes. Eur J Endocrinol 150: 799-807, 2004.
4. Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: A multifunctional angiogenic cytokine. EXS 79: 233-269, 1997.
5. Cao H, Courchesne WE, Mastick CC. A phosphotyrosine-dependent protein interaction screen reveals a role for phosphorylation of caveolin-1 on tyrosine 14: recruitment of C-terminal Src kinase. J Biol Chem 277: 8771-8774, 2002.
6. Casalou C, Fragoso R, Nunes JF, Dias S. VEGF/PLGF induces leukemia cell migration via P38/ERK1/2 kinase pathway, resulting in Rho GTPases activation and caveolae formation. Leukemia 21: 1590-1594, 2007.
7. Chen S, Ziyadeh FN. Vascular endothelial growth factor and diabetic nephropathy. Curr Diab Rep 8: 470-476, 2008.
8. Chidlow JH Jr, Sessa WC. Caveolae, caveolins, and cavins: complex control of cellular signalling and inflammation. Cardiovasc Res 86: 219-225, 2010.
9. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, Casley DJ, Bach LA, Kelly DJ, Gilbert RE. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 48: 2229-2239, 1999.
10. Couet J, Sargiacomo M, Lisanti MP. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem 272: 30429-30438, 1997.
11. Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L. VEGF-recep-tor signal transduction. Trends Biochem Sci 28: 488-494, 2003.
12. Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL. Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat Cell Biol 5: 410-421, 2003.
13. Doi K, Noiri E, Fujita T. Role of vascular endothelial growth factor in kidney disease. Curr Vasc Pharmacol 8: 122-128, 2010.
14. Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J, Lindschau C, Mende F, Luft FC, Schedl A, Haller H, Kurzchalia TV. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293: 2449-2452, 2001.
15. Esser S, Wolburg K, Wolburg H, Breier G, Kurzchalia T, Risau W. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol 140: 947-959, 1998.
16. Feng Y, Venema VJ, Venema RC, Tsai N, Behzadian MA, Caldwell RB. VEGF-induced permeability increase is mediated by caveolae. Invest Ophthalmol Vis Sci 40: 158-167, 1999.
17. Feng Y, Venema VJ, Venema RC, Tsai N, Caldwell RB. VEGF induces nuclear translocation of Flk-1/KDR, endothelial nitric oxide synthase, and caveolin-1 in vascular endothelial cells. Biochem Biophys Res Commun 256: 192-197, 1999.
18. Ferrara N, Houck KA, Jakeman LB, Winer J, Leung DW. The vascular endothelial growth factor family of polypeptides. J Cell Biochem 47: 211-218, 1991.
19. Foster RR. The importance of cellular VEGF bioactivity in the development of glomerular disease. Nephron Exp Nephrol 113: e8-e15, 2009.
20. Fujioka K, Azuma N, Kito H, Gahtan V, Esato K, Sumpio BE. Role of caveolin in hemodynamic force-mediated endothelial changes. J Surg Res 92: 7-10, 2000.
21. Ha H, Lee HB. Reactive oxygen species and matrix remodeling in diabetic kidney. J Am Soc Nephrol 14, Suppl 3: S246-249, 2003.
22. He H, Venema VJ, Gu X, Venema RC, Marrero MB, Caldwell RB. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem 274: 25130-25135, 1999.
23. Kang DH, Johnson RJ. Vascular endothelial growth factor: a new player in the pathogenesis of renal fibrosis. Curr Opin Nephrol Hypertens 12: 43-49, 2003.
24. Kanwar YS, Wada J, Lin S, Danesh FR, Chugh SS, Yang Q, Banerjee T, Lomasney JW. Update of extracellular matrix, its receptors and cell adhesion molecules in mammalian nephrogenesis. Am J Physiol Renal Physiol 286: F202-F215, 2004.
25. Kanwar YS, Wada J, Sun L, Xie P, Wallner EI, Chen S, Chugh S, Danesh FR. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med (Maywood) 233: 4-11, 2008.
26. Kim YN, Wiepz GJ, Guadarrama AG, Bertics PJ. Epidermal growth factor-stimulated tyrosine phosphorylation of caveolin-1. Enhanced caveolin-1 tyrosine phosphorylation following aberrant epidermal growth factor receptor status. J Biol Chem 275: 7481-7491, 2000.
27. Kirkham M, Parton RG. Clathrin-independent endocytosis: new insights into caveolae and non-caveolar lipid raft carriers. Biochim Biophys Acta 1745: 273-286, 2005.
28. Krepinsky JC, Ingram AJ, Tang D, Wu D, Liu L, Scholey JW. Nitric oxide inhibits stretch-induced MAPK activation in mesangial cells through RhoA inactivation. J Am Soc Nephrol 14: 2790-2800, 2003.
29. Labrecque L, Royal I, Surprenant DS, Patterson C, Gingras D, Béliveau R. Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol Biol Cell 14: 334-347, 2003.
30. Li S, Seitz R, Lisanti MP. Phosphorylation of caveolin by src tyrosine kinases. The alpha-isoform of caveolin is selectively phosphorylated by v-Src in vivo. J Biol Chem 271: 3863-3868, 1996.
31. Liao WX, Feng L, Zhang H, Zheng J, Moore TR, Chen DB. Compartmentalizing VEGF-induced ERK2/1 signaling in placental artery endothe-lial cell caveolae: a paradoxical role of caveolin-1 in placental angiogen-esis in vitro. Mol Endocrinol 23: 1428-1444, 2009.
32. Liu E, Morimoto M, Kitajima S, Koike T, Yu Y, Shiiki H, Nagata M, Watanabe T, Fan J. Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. J Am Soc Nephrol 18: 2094-2104, 2007.
33. Liu J, Razani B, Tang S, Terman BI, Ware JA, Lisanti MP. Angio-genesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells. Angiogenesis inhibitors block vascular endothelial growth factor-induced downregula-tion of caveolin-1. J Biol Chem 274: 15781-15785, 1999.
34. Liu P, Rudick M, Anderson RG. Multiple functions of caveolin-1. J Biol Chem 277: 41295-41298, 2002.
35. Liu P, Ying Y, Ko YG, Anderson RG. Localization of platelet-derived growth factor-stimulated phosphorylation cascade to caveolae. J Biol Chem 271: 10299-10303, 1996.
36. Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 14: 1358-1373, 2003.
37. Mastick CC, Saltiel AR. Insulin-stimulated tyrosine phosphorylation of caveolin is specific for the differentiated adipocyte phenotype in 3T3-L1 cells. J Biol Chem 272: 20706-20714, 1997.
38. McLennan SV, Death AK, Fisher EJ, Williams PF, Yue DK, Turtle JR. The role of the mesangial cell and its matrix in the pathogenesis of diabetic nephropathy. Cell Mol Biol 45: 123-135, 1999.
39. Mineo C, Gill GN, Anderson RG. Regulated migration of epidermal growth factor receptor from caveolae. J Biol Chem 274: 30636-30643, 1999.
40. Mironidou-Tzouveleki M, Tsartsalis S, Tomos C. Vascular endothelial growth factor (VEGF) in the pathogenesis of diabetic nephropathy of type 1 diabetes mellitus. Curr Drug Targets 12: 107-114, 2011.
41. Nakagawa T. A new mouse model resembling human diabetic nephrop-athy: uncoupling of VEGF with eNOS as a novel pathogenic mechanism. Clin Nephrol 71: 103-109, 2009.
42. Okamoto T, Schlegel A, Scherer PE, Lisanti MP. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem 273: 5419-5422, 1998.
43. Ortegren U, Aboulaich N, Ost A, Strålfors P. A new role for caveolae as metabolic platforms. Trends Endocrinol Metab 18: 344-349, 2007.
44. Parat MO. The biology of caveolae: achievements and perspectives. Int Rev Cell Mol Biol 273: 117-162, 2009.
45. Peng F, Wu D, Ingram AJ, Zhang BF, Gao B, Krepinsky JC. RhoA activation in mesangial cells by mechanical strain depends on caveolae and caveolin-1 interaction. J Am Soc Nephrol 18: 189-198, 2007.
46. Peng F, Zhang BF, Wu D, Ingram AJ, Gao B, Krepinsky JC. TGF-induced RhoA activation and fibronectin production in mesangial cells require caveolae. Am J Physiol Renal Physiol 295: F153-F164, 2008.
47. Quest AF, Gutierrez-Pajares JL, Torres VA. Caveolin-1: an ambiguous partner in cell signalling and cancer. J Cell Mol Med 12: 1130-1150, 2008.
48. Razani B, Woodman SE, Lisanti MP. Caveolae: from cell biology to animal physiology. Pharmacol Rev 54: 431-467, 2002.
49. Sato W, Tanabe K, Kosugi T, Hudkins K, Lanaspa MA, Zhang L, Campbell-Thompson M, Li Q, Long DA, Alpers CE, Nakagawa T. Selective stimulation of VEGFR2 accelerates progressive renal disease. Am J Pathol 179: 155-166, 2011.
50. Schlegel A, Pestell RG, Lisanti MP. Caveolins in cholesterol trafficking and signal transduction: implications for human disease. Front Biosci 5: D929-D937, 2000.
51. Schnitzer JE, Oh P, Pinney E, Allard J. Filipin-sensitive caveolae-mediated transport in endothelium: reduced transcytosis, scavenger endo-cytosis, and capillary permeability of select macromolecules. J Cell Biol 127: 1217-1232, 1994.
52. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endo-thelial growth factor (VEGF) in renal pathophysiology. Kidney Int 65: 2003-2017, 2004.
53. Schwencke C, Braun-Dullaeus RC, Wunderlich C, Strasser RH. Cave-olae and caveolin in transmembrane signaling: Implications for human disease. Cardiovasc Res 70: 42-49, 2006.
54. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312: 549-560, 2006.
55. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropi-lin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92:735-745, 1998.
56. Tahara A, Tsukada J, Tomura Y, Yatsu T, Shibasaki M. Vasopressin regulates rat mesangial cell growth by inducing autocrine secretion of vascular endothelial growth factor. J Physiol Sci 61: 115-122, 2011.
57. Takahashi T, Shirasawa T, Miyake K, Yahagi Y, Maruyama N, Kasahara N, Kawamura T, Matsumura O, Mitarai T, Sakai O. Protein tyrosine kinases expressed in glomeruli and cultured glomerular cells: Flt-1 and VEGF expression in renal mesangial cells. Biochem Biophys Res Commun 209: 218-226, 1995.
58. Tamai O, Oka N, Kikuchi T, Koda Y, Soejima M, Wada Y, Fujisawa M, Tamaki K, Kawachi H, Shimizu F, Kimura H, Imaizumi T, Okuda S. Caveolae in mesangial cells and caveolin expression in mesangial proliferative glomerulonephritis. Kidney Int 59: 471-480, 2001.
59. Thomas S, Vanuystel J, Gruden G, Rodriguez V, Burt D, Gnudi L, Hartley B, Viberti G. Vascular endothelial growth factor receptors in human mesangium in vitro, and in glomerular disease. J Am Soc Nephrol 11: 1236-1243, 2000.
60. Tiruppathi C, Song W, Bergenfeldt M, Sass P, Malik AB. Gp60 activation mediates albumin transcytosis in endothelia cells by tyrosine kinase-dependent pathway. J Biol Chem 272: 25968-25975, 1997.
61. Treins C, Giorgetti-Peraldi G, Murdaca J, Semenza GL, Van Obberghen E. Regulation of vascular endothelial growth factor expression by advanced glycation end products. J Biol Chem 276: 48836-48841, 2001.
62. Ushio-Fukai M, Hilenski L, Santanam N, Becker PL, Ma Y, Grien-dling KK, Alexander RW. Cholesterol depletion inhibits epidermal growth factor receptor transactivation by angiotensin II in vascular smooth muscle cells: Role of cholesterol-rich microdomains and focal adhesions in angiotensin II signaling. J Biol Chem 276: 48269-48275, 2001.
63. Wakelin SJ, Marson L, Howie SE, Garden J, Lamb JR, Forsythe JL. The role of vascular endothelial growth factor in the kidney in health and disease. Nephron Physio 98: 73-79, 2004.
64. Wang L, Kwak JH, Kim SI, He Y, Choi ME. Transforming growth factor-beta1 stimulates vascular endothelial growth factor 164 via mito-gen-activated protein kinase kinase 3-p38alpha and p38delta mitogen-activated protein kinase-dependent pathway in murine mesangial cells. J Biol Chem 279: 33213-33219, 2004.
65. Whiteside C, Wang H, Xia L, Munk S, Goldberg HJ, Fantus IG. Rosiglitazone prevents high glucose-induced vascular endothelial growth factor and collagen IV expression in cultured mesangial cells. Exp Diabetes Res 2009: 910783, 2009.
66. Xia L, Wang H, Munk S, Frecker H, Goldberg HJ, Fantus IG, Whiteside CI. Reactive oxygen species, PKC-beta1, and PKC-zeta mediate high-glucose-induced vascular endothelial growth factor expression in mesangial cells. Am J Physiol Endocrinol Metab 293: E1280-E1288, 2007.
67. Xu H, Zeng L, Peng H, Chen S, Jones J, Chew TL, Sadeghi MM, Kanwar YS, Danesh FR. HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced "inside-out" signaling to extracellular matrix by preventing RhoA activation. Am J Physiol Renal Physiol 291: F995- F1004, 2006.
68. Yamamoto M, Toya Y, Schwencke C, Lisanti MP, Myers MG Jr, Ishikawa Y. Caveolin is an activator of insulin receptor signaling. J Biol Chem 273: 26962-26968, 1998.
69. Zacharias DA, Violin JD, Newton AC, Tsien RY. Partitioning of lipid-modified monomeric GFPs into membrane microdomains of live cells. Science 296: 913-916, 2002.